The impact of type 2 diabetes on the outcome of localized renal cell carcinoma

World Journal of Urology

Volumn 32, Issue 6, 2014, Pages 1537-1542

  Höfner, Thomas ^a   Zeier, Martin ^a   Hatiboglu, Gencay ^a   Eisen, Christian ^b   Schönberg, Gita ^a   Hadaschik, Boris ^a   Teber, Dogu ^a   Duensing, Stefan ^a   Trumpp, Andreas ^b   Hohenfellner, Markus ^a   Pahernik, Sascha ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Diabetes; Kidney cancer; Obesity; Outcomes; Risk factors; Survival

Indexed keywords

AGED; BODY MASS; CARCINOMA, RENAL CELL; COMPLICATION; DISEASE FREE SURVIVAL; FEMALE; HUMAN; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MORTALITY; NEPHRECTOMY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOLOGY; RETROSPECTIVE STUDY; RISK FACTOR; SURVIVAL RATE; TREATMENT OUTCOME;

AGED; BODY MASS INDEX; CARCINOMA, RENAL CELL; DIABETES MELLITUS, TYPE 2; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEPHRECTOMY; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84912032332     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-013-1231-z     Document Type: Article

References (29)

1. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M (2008) Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 371(9612):569–578. doi:10.1016/S0140-6736(08)60269-X
2. Smyth S, Heron A (2006) Diabetes and obesity: the twin epidemics. Nat Med 12(1):75–80. doi:10.1038/nm0106-75
3. Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, Pollak M, Regensteiner JG, Yee D (2010) Diabetes and cancer: a consensus report. CA Cancer J Clin 60(4):207–221. doi:10.3322/caac.20078
4. Barone BB, Yeh HC, Snyder CF, Peairs KS, Stein KB, Derr RL, Wolff AC, Brancati FL (2008) Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. JAMA 300(23):2754–2764. doi:10.1001/jama.2008.824
5. Danaei G, Finucane MM, Lu Y, Singh GM, Cowan MJ, Paciorek CJ, Lin JK, Farzadfar F, Khang YH, Stevens GA, Rao M, Ali MK, Riley LM, Robinson CA, Ezzati M (2011) National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet 378(9785):31–40. doi:10.1016/S0140-6736(11)60679-X
6. Xu X, Wu J, Mao Y, Zhu Y, Hu Z, Lin Y, Chen H, Zheng X, Qin J, Xie L (2013) Diabetes mellitus and risk of bladder cancer: a meta-analysis of cohort studies. PLoS ONE 8(3):e58079. doi:10.1371/journal.pone.0058079
7. Lawrence YR, Morag O, Benderly M, Boyko V, Novikov I, Dicker AP, Goldbourt U, Behar S, Barchana M, Wolf I (2013) Association between metabolic syndrome, diabetes mellitus and prostate cancer risk. Prostate Cancer Prostatic Dis. doi:10.1038/pcan.2012.54
8. Fall K, Garmo H, Gudbjornsdottir S, Stattin P, Zethelius BO (2013) Diabetes mellitus and prostate cancer risk: a nationwide case–control study within PCBASE Sweden. Cancer Epidemiol Biomarkers Prev. doi:10.1158/1055-9965.EPI-12-1046
9. Lee S, Hong SK, Kwak C, Kim HH, Lee SE (2012) Prognostic significance of diabetes mellitus in localized renal cell carcinoma. Jpn J Clin Oncol 42(4):318–324. doi:10.1093/jjco/hys018
10. Antonelli A, Arrighi N, Corti S, Zanotelli T, Cozzoli A, Cosciani Cunico S, Simeone C (2012) Pre-existing type-2 diabetes is not an adverse prognostic factor in patients with renal cell carcinoma: a single-center retrospective study. Urol Oncol. doi:10.1016/j.urolonc.2011.12.013
11. Huber J, Herpel E, Jakobi H, Hadaschik BA, Pahernik S, Hohenfellner M (2012) Two decades’ experience with a prospective biobank for urologic oncology: research, clinical care, and the patients’ view. Urol Oncol. doi:10.1016/j.urolonc.2012.01.016
12. Hess KR (1995) Graphical methods for assessing violations of the proportional hazards assumption in cox regression. Stat Med 14(15):1707–1723
13. Ha YS, Kim WT, Yun SJ, Lee SC, Kim WJ, Park YH, Kang SH, Hong SH, Byun SS, Kim YJ (2013) Multi-institutional analysis of localized renal cell carcinoma that demonstrates the impact of diabetic status on prognosis after nephrectomy. Ann Surg Oncol 20(11):3662–3668. doi:10.1245/s10434-013-3147-7
14. Suer E, Ozturk E, Gulpinar O, Kayis A, Baltaci S (2013) Effect of type 2 diabetes mellitus on prognosis of nonmetastatic renal cell cancer. Korean J Urol 54(8):499–503. doi:10.4111/kju.2013.54.8.499
15. Fukushima H, Masuda H, Yokoyama M, Tatokoro M, Yoshida S, Ishioka J, Matsuoka Y, Numao N, Koga F, Saito K, Fujii Y, Kihara K (2013) Diabetes mellitus with obesity is a predictor of recurrence in patients with non-metastatic renal cell carcinoma. Jpn J Clin Oncol 43(7):740–746. doi:10.1093/jjco/hyt070
16. Seshasai SR, Kaptoge S, Thompson A, Di Angelantonio E, Gao P, Sarwar N, Whincup PH, Mukamal KJ, Gillum RF, Holme I, Njolstad I, Fletcher A, Nilsson P, Lewington S, Collins R, Gudnason V, Thompson SG, Sattar N, Selvin E, Hu FB, Danesh J (2011) Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 364(9):829–841. doi:10.1056/NEJMoa1008862
17. Brower V (2012) Illuminating the diabetes–cancer link. J Natl Cancer Inst 104(14):1048–1050. doi:10.1093/jnci/djs322
18. Ferrannini E, Cushman WC (2012) Diabetes and hypertension: the bad companions. Lancet 380(9841):601–610. doi:10.1016/S0140-6736(12)60987-8
19. Ito K, Nakashima J, Hanawa Y, Oya M, Ohigashi T, Marumo K, Murai M (2004) The prediction of renal function 6 years after unilateral nephrectomy using preoperative risk factors. J Urol 171(1):120–125. doi:10.1097/01.ju.0000100981.11470.2f
20. Kodama S, Tanaka S, Heianza Y, Fujihara K, Horikawa C, Shimano H, Saito K, Yamada N, Ohashi Y, Sone H (2013) Association between physical activity and risk of all-cause mortality and cardiovascular disease in patients with diabetes: a meta-analysis. Diabetes Care 36(2):471–479. doi:10.2337/dc12-0783
21. Habib SL, Prihoda TJ, Luna M, Werner SA (2012) Diabetes and risk of renal cell carcinoma. J Cancer 3:42–48. doi:10.7150/jca.3718
22. Hellemons ME, Kerschbaum J, Bakker SJ, Neuwirt H, Mayer B, Mayer G, de Zeeuw D, Lambers Heerspink HJ, Rudnicki M (2012) Validity of biomarkers predicting onset or progression of nephropathy in patients with type 2 diabetes: a systematic review. Diabet Med 29(5):567–577. doi:10.1111/j.1464-5491.2011.03437.x
23. Abouassaly R, Finelli A, Tomlinson GA, Urbach DR, Alibhai SM (2011) How often are patients with diabetes or hypertension being treated with partial nephrectomy for renal cell carcinoma? A population-based analysis. BJU Int 108(11):1806–1812. doi:10.1111/j.1464-410X.2011.10254.x
24. Filson CP, Schwartz K, Colt JS, Ruterbusch J, Linehan WM, Chow WH, Miller DC (2013) Use of nephron-sparing surgery among renal cell carcinoma patients with diabetes and hypertension. Urol Oncol. doi:10.1016/j.urolonc.2012.09.014
25. Stolarczyk E, Vong CT, Perucha E, Jackson I, Cawthorne MA, Wargent ET, Powell N, Canavan JB, Lord GM, Howard JK (2013) Improved insulin sensitivity despite increased visceral adiposity in mice deficient for the immune cell transcription factor T-bet. Cell Metab 17(4):520–533. doi:10.1016/j.cmet.2013.02.019
26. Liew CW, Boucher J, Cheong JK, Vernochet C, Koh HJ, Mallol C, Townsend K, Langin D, Kawamori D, Hu J, Tseng YH, Hellerstein MK, Farmer SR, Goodyear L, Doria A, Bluher M, Hsu SI, Kulkarni RN (2013) Ablation of TRIP-Br 2, a regulator of fat lipolysis, thermogenesis and oxidative metabolism, prevents diet-induced obesity and insulin resistance. Nat Med 19(2):217–226. doi:10.1038/nm.3056
27. Rose S, Laan MJ (2009) Why match? Investigating matched case–control study designs with causal effect estimation. Int J Biostat 5 (1): Article 1. doi:10.2202/1557-4679.1127
28. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics. CA Cancer J Clin 63(1):11–30. doi:10.3322/caac.21166
29. Grimes DA, Schulz KF (2005) Compared to what? Finding controls for case–control studies. Lancet 365(9468):1429–1433. doi:10.1016/S0140-6736(05)66379-9